Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management
Ozgur Mete, Andrée Boucher, Kasmintan A Schrader, Omar Abdel-Rahman, Houda Bahig, Cheryl Ho, Olfat Kamel Hasan, Bernard Lemieux, Eric Winquist, Ralph Wong, Jonn Wu, Nicole Chau, Shereen Ezzat · 2024
Read Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management by Ozgur Mete, Andrée Boucher, Kasmintan A Schrader, Omar Abdel-Rahman, Houda Bahig, Cheryl Ho, Olfat Kamel Hasan, Bernard Lemieux, Eric Winquist, Ralph Wong, Jonn Wu, Nicole Chau, Shereen Ezzat (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11659332.txt.
Description
Ozgur Mete and a panel of experts issue consensus advice in 2024 on biomarker testing for thyroid cancer. Gene tests on inherited and tumor DNA now guide targeted treatment, but testing practice varies and patients are missed. The panel reviewed world guidelines and the evidence for tests that can change care.
Algorithms are given for the main thyroid cancer types, from medullary to the most aggressive anaplastic form. The advice stays neutral about which drug to use, so it fits many health systems and budgets. Gaps in testing access are discussed, with stress on team based care. The aim is steady, fair application of biomarker testing in practice.
Catalog record
| CREATOR | Ozgur Mete, Andrée Boucher, Kasmintan A Schrader, Omar Abdel-Rahman, Houda Bahig, Cheryl Ho, Olfat Kamel Hasan, Bernard Lemieux, Eric Winquist, Ralph Wong, Jonn Wu, Nicole Chau, Shereen Ezzat |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |